{"id":"NCT01175213","sponsor":"Baxalta now part of Shire","briefTitle":"Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID","officialTitle":"Long-Term Tolerability and Safety of Immune Globulin Subcutaneous (IGSC) Solution Administered Subcutaneously Following Administration of Recombinant Human Hyaluronidase (rHuPH20) in Subjects With Primary Immunodeficiency Diseases","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-07-28","primaryCompletion":"2013-08-06","completion":"2013-08-06","firstPosted":"2010-08-04","resultsPosted":"2016-05-26","lastUpdate":"2021-05-19"},"enrollment":66,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Primary Immunodeficiency Diseases (PID)"],"interventions":[{"type":"BIOLOGICAL","name":"SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety)","otherNames":["HYQVIA (IGSC","10% with rHuPH20 [US])","10% with rHuPH20 [EU])","GAMMAGARD LIQUID (IGSC","10% [US])","KIOVIG (IGSC","10% [EU])"]},{"type":"BIOLOGICAL","name":"SC treatment with IGSC, 10% with rHuPH20 followed by IV/IGSC, 10% only (safety)","otherNames":["GAMMAGARD LIQUID (IGSC","10% [US])","KIOVIG (IGSC","10% [EU])","HyQvia (IGSC","10% with rHuPH20 [EU])","10% with rHuPH20 [US])"]},{"type":"BIOLOGICAL","name":"IV treatment with IGSC, 10%","otherNames":["GAMMAGARD LIQUID (US)","KIOVIG (EU)"]}],"arms":[{"label":"SC/IGSC, 10% with rHuPH20 followed by SC of IGSC, 10% (safety)","type":"EXPERIMENTAL"},{"label":"SC/IGSC, 10% with rHuPH20 followed by IV of IGSC, 10% (safety","type":"EXPERIMENTAL"},{"label":"IV treatment with IGSC, 10% only","type":"EXPERIMENTAL"}],"summary":"The original purpose of the study is to assess the long-term safety, tolerability, and practicability of the subcutaneous (SC) treatment with Immune Globulin Subcutaneous Solution (IGSC), 10% facilitated with recombinant human hyaluronidase (rHuPH20) in participants with Primary Immunodeficiency Diseases (PID) who have completed Baxter Clinical Study Protocol No. 160603.\n\nFollowing a discussion with the FDA, all participants still active in the study stopped treatment with rHuPH20 to assure safety of the participants participating in the study and went into a safety follow-up.\n\nDuring this safety follow-up period, participants underwent either intravenous (IV) or SC treatment with IGSC, 10%. The IV or SC administration route was at the discretion of the participant and the investigator.","primaryOutcome":{"measure":"Annual Rate of Serious Bacterial Infections","timeFrame":"Throughout the efficacy period only (from 60 to 729 days)","effectByArm":[{"arm":"All Participants Treated With IGSC, 10% and rHuPH20","deltaMin":0.02,"sd":null}],"pValues":[{"comp":"OG000","p":"<0.0001"}]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":11,"countries":["United States"]},"refs":{"pmids":["27220317","34931880"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":63},"commonTop":["Sinusitis","Headache","Upper Respiratory Tract Infection","Nausea","Bronchitis"]}}